Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer
NCT ID: NCT06614660
Last Updated: 2024-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
800 participants
OBSERVATIONAL
2024-09-01
2027-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Environmental Factors and Metabolomics on Colorectal Cancer.
NCT06643429
Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods
NCT05501353
Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Colorectal Cancer Patients
NCT06614699
Constructing a Multimodal Imaging System to Predict the Risk of Heterochronous Metastasis of Rectal Cancer
NCT06293612
Genomic Signatures for Patients With Initially Unresectable Colorectal Liver Metastases
NCT06477718
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1\. Data collection before and after surgical treatment
1. Study subjects: patients diagnosed with colorectal cancer and voluntarily undergoing radical colorectal cancer surgery in the First Affiliated Hospital of Chongqing Medical University will be included; preoperative imaging images will be collected before surgery, and 2 ml of blood specimens will be collected from the patients for imaging and metabolomics studies.
2. Follow-up efficacy judgement: the study subjects included in this project were followed up after undergoing surgery, and the overall survival (OS) and disease-free survival (DFS) of the study subjects should be followed up for at least 3 years.
2\. Using pre-treatment colorectal cancer imaging images, study the imaging histological features that predict the prognosis of colorectal cancer patients, and develop an imaging histological prediction model for colorectal cancer.
1. Construct an imaging histology prediction model for colorectal cancer based on the imaging images of the study subjects, and then randomly assign them to the training cohort and validation cohort by the computer according to 7:3 to carry out model evaluation. For imaging histology model development and internal validation, deep learning methods are applied for imaging histology feature extraction to extract two main categories of image features: one is manually defined features such as tumour shape, intensity, texture and wavelets, and the other is non-specified features extracted using convolutional neural networks. For the manually defined features, the investigators extract the features of colorectal cancer cancer foci. The cancer foci are outlined on the imaging images by radiologists, and four types of image features, namely, shape, intensity, texture and wavelet transform, are extracted from the cancer foci. The specific requirements are: the features extracted by shape are compatible with the doctor\'s visual judgement, e.g., the outline is not glossy, the edges are blurred, etc.; the features extracted by intensity can reflect the homogeneous nature of the foci, etc.: the features extracted by texture and wavelet transform belong to the high-dimensional complex features. can mine information that cannot be extracted by doctors\' vision. For feature extraction by convolutional neural network, the region of interest (ROI) of colorectal cancer foci is firstly sketched, and adaptive features are learnt for specific targets through supervised learning. Convolutional neural network carries out layer-by-layer nonlinear transformation and convolution operation on massive image data, and its learnt features are more targeted and adaptive than the manually designed features. Fusing the two major categories of extracted image features, the idea of combining statistical analysis and multiple machine learning feature selection methods is used to screen all the extracted features for stability and repeatability, and key features with high stability, high differentiation and high independence are obtained for subsequent development of prediction models.
2. To develop an imaging histology prediction model for colorectal cancer and elucidate the feasibility of imaging histology in predicting the prognosis of colorectal cancer patients. Using the colorectal cancer imaging features, clinical information and pathological diagnostic information selected from the research subjects included in the study as input information, and by combining a variety of existing advanced machine-learning algorithms (vector machine, random forest, AdaBoost, deep learning, etc.), cross validation is used to ensure the reliability and stability of the model, and ultimately a final design is developed that can use imaging to predict the prognosis of colorectal cancer. Imaging histology prediction model. The model should be internally validated in the validation cohort first after its establishment, and should also be externally validated because external validation of model data is generally considered to be more independent and strengthens the validation to elucidate the feasibility of imaging histology to evaluate the prognosis of colorectal cancer.
3\. Development of imaging-metabolomics prediction models related to colorectal cancer prognosis.
1. To study the metabolomic markers related to the prognosis of colorectal cancer patients using cancer tissues and blood specimens of the study subjects.
2. Metabolomics testing was performed based on blood specimens from the study subjects. Metabolomic fingerprinting was used for the metabolomics study, in which liquid chromatography-mass spectrometry (LC-MS) was used to compare the respective metabolites of treatment-resistant and effective ESCC tissues in order to identify all the metabolites therein. Metabolic fingerprinting involves comparing the mass spectrometry peaks of metabolites in different individuals to ultimately understand the structure of different compounds and to establish a complete set of analytical methods for identifying the characteristics of these different compounds. The steps of non-targeted metabolomics assay are as follows: 1) Obtaining sample information: quality control (QC) samples are prepared for determining the state of the instrument and the equilibrium chromatography-mass spectrometry (CS-MS) system prior to sampling and are used to evaluate. The stability of the system throughout the experiment.2) Sample pre-processing.3) Chromatography-mass spectrometry analysis.4) Data processing to identify differential metabolites.5) Differential metabolite metabolism.6) Sample analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
the colorectal cancer group
Metabolism genomics and imaging genomics were collected via blood and CT images for colorectal cancer patients.
Metabolism genomics and imaging genomics
Pre-operative imaging images of the patient were collected prior to surgery, and 2 ml of the patient\'s blood specimen was collected to collect metabolism genomics and imaging genomics.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metabolism genomics and imaging genomics
Pre-operative imaging images of the patient were collected prior to surgery, and 2 ml of the patient\'s blood specimen was collected to collect metabolism genomics and imaging genomics.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age \>18 years;
* planned to undergo surgery for gastrointestinal tumours according to the guidelines;
* signed an informed consent form; and e) agreed to undergo a biopsy in order to collect tissue from the tumour lesion.
Exclusion Criteria
* withdrawal from the study cohort midway;
* metastatic foci in the liver, lung or other distant organs confirmed by CT, MRI or ultrasound imaging;
* gastrointestinal tumours combined with haemorrhage, obstruction or perforation;
* women who were pregnant, breastfeeding or planning to become pregnant during the study period.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Chongqing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dong Peng
Dr.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zhang G, Zhang Z, Pei Y, Hu W, Xue Y, Ning R, Guo X, Sun Y, Zhang Q. Biological and clinical significance of radiomics features obtained from magnetic resonance imaging preceding pre-carbon ion radiotherapy in prostate cancer based on radiometabolomics. Front Endocrinol (Lausanne). 2023 Oct 20;14:1272806. doi: 10.3389/fendo.2023.1272806. eCollection 2023.
Cicalini I, Chiarelli AM, Chiacchiaretta P, Perpetuini D, Rosa C, Mastrodicasa D, d'Annibale M, Trebeschi S, Serafini FL, Cocco G, Narciso M, Corvino A, Cinalli S, Genovesi D, Lanuti P, Valentinuzzi S, Pieragostino D, Brocco D, Beets-Tan RGH, Tinari N, Sensi SL, Stuppia L, Del Boccio P, Caulo M, Delli Pizzi A. Multi-omics staging of locally advanced rectal cancer predicts treatment response: a pilot study. Radiol Med. 2024 May;129(5):712-726. doi: 10.1007/s11547-024-01811-0. Epub 2024 Mar 27.
Pan Y, Lei X, Zhang Y. Association predictions of genomics, proteinomics, transcriptomics, microbiome, metabolomics, pathomics, radiomics, drug, symptoms, environment factor, and disease networks: A comprehensive approach. Med Res Rev. 2022 Jan;42(1):441-461. doi: 10.1002/med.21847. Epub 2021 Aug 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
204-160-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.